Radical retropubic prostatectomy (RRP) is an important cause of iatrogenic erectile dysfunction (ED). While sildena®l has been widely used since its introduction as a new treatment option for ED, its ef®cacy in post-RRP patients has not been extensively studied. We retrospectively compared the ef®cacy of sildena®l in post-RRP and non-surgical patients with ED (NSED) using a subset of questions from the International Index of Erectile Function (IIEF) and correlated results with their speci®c etiology of ED based on penile blood¯ow study (PBFS).
Introduction
Radical retropubic prostatectomy (RRP) is one of the most common causes of iatrogenic erectile dysfunction (ED). Until recently, the main therapeutic options for impotence secondary to prostatectomy were intracavernosal injection therapy with vasoactive substances (ICI), intraurethral administration of alprostadil, vacuum erection devices, and penile prosthesis implantation. The clinical availability of Viagra 1 (sildena®l citrate ± P®zer Pharmaceuticals, New York, USA) has presented a new option for these patients, but its ef®cacy in this population has not been extensively studied.
The International Index of Erectile Function 1 is a validated instrument which has been used to assess the ef®cacy of sildena®l in clinical trials. 2, 3 Nevertheless, few studies have used this instrument to speci®cally evaluate the erectile activity of post-RRP patients. The penile blood¯ow study with duplex Doppler ultrasound (PBFS) is a diagnostic test that provides speci®c information regarding the vascular etiology of ED. This examination is useful in characterizing the hemodynamic state of the penile vasculature during erection, differentiating between normal vascular responses (pure neurogenic ED), arterial insuf®ciency, venous leakage, and mixed vascular erectile dysfunction. We categorized the vascular status of a group of post-RRP patients, and then compared those responses to age-matched patients complaining of ED with no prior pelvic surgery history (NSED). Post-treatment IIEF scores to questions 3 and 4 were compared, as well as their responses to sildena®l. Underlying vascular pathophysiology was characterized by standardized pharmacotesting with PGE1 and color duplex Doppler.
Materials and methods
Between July 1997 and August 1998, 72 consecutive patients complaining of erectile dysfunction after RRP and 32 age matched non-surgical patients with ED (NSED) underwent penile blood¯ow studies with duplex Doppler ultrasound (PBFS) and were subsequently treated with sildena®l. All patients completed a modi®ed IIEF questionnaire following treatment with sildena®l. The questionnaire included questions 3 and 4 from the IIEF, which assess the ability to initiate and maintain erection prior to treatment, along with several speci®c questions about sildena®l responses (Table 1) . We chose questions 3 and 4 (Q 3 4) because the Viagra Study Group had used this subset of questions as the primary ef®cacy endpoint. 2 A score of 5 (scale 1 ± 5) is expected in a normal individual on any single element of the IIEF. 1 Likewise, a total score of 10 (Q3 4) in the Viagra Study Group suggested normal erectile function. Mean scores for questions 3 and 4 were calculated for each diagnostic group; penile blood¯ow parameters and visual ratings of erections following prostaglandin E1 (PGE1) pharmacotesting were recorded. Patients were asked to report their answer to question D as a percentage from 0 to 100%. Mean satisfaction scores for each group were also calculated. For this study, patients were considered to have had successful therapy if they reported moderate or excellent improvement with their ability to penetrate and maintain an erection and would recommend the drug to a friend.
All patients underwent a complete history and physical examination. At a separate appointment, all patients underwent a penile blood¯ow study following age-speci®c dosing of PGE1. Patients younger than 60 y were given 6 mcg, while patients 60 y or older were given 10 mcg. All patients were then studied by color duplex Doppler ultrasound (CDDU) before and after privacy with selfstimulation.
All studies were performed using a 7.5 MHz linear transducer with standoff wedge to maximize near-®eld imaging (Siemens Quantum, Issaquah, WA). Flow velocities were measured in the sagittal plane of the proximal pendulous shaft with the penis held extended. Cavernous arteries were assessed bilaterally for peak systolic velocity (PSV), end diastolic velocity (EDV), and resistive index (R1). One investigator (GAB) performed diagnostic testing and rated erections according to the scale in Table 2 . Statistical analysis was performed using SigmaStat software.
Results
Seventy-two post-RRP patients and 32 NSED patients underwent the complete evaluation as outlined. Results of their PBFS are summarized in Table 3 . Twelve post RRP patients had normal PBFS and ADE or EXC erectile response suggesting neurogenic dysfunction. Sixty post-RRP patients (83%) had INA erectile responses and Doppler criteria of vascular ED and were further subcategorized based on their blood¯ow studies. Thirty-two (44%) with mean PSV`25 cmasec were classi®ed as having severe arterial insuf®ciency (AI). Six patients (8%) with mean PSV b 35 cmasec were classi®ed as having severe cavernous venous occlusive disease (CVOD) and 22 patients (31%) with PSV 25 cmasec but 35 cmasec were classi®ed as having mixed vascular erectile dysfunction. 4 Of the 32 NSED patients, 14 (44%) had A1, and 14 (44%) had mixed vascular erectile dysfunction. The remaining four patients (12%) had CVOD.
The NSED patients had a mean post-treatment Q 3 4 score of 7.0 (scale 0 ± 10); their satisfaction rate with sildena®l was 63%. The mean Q 3 4 score of the RRP patients was 4.7, and this group had a 31% Table 1 Modi®ed IIEF questionnaire A) Over the past 4 weeks, when you attempted sexual intercourse, how often were you able to penetrate (enter) your partner?* B) Over the past 4 weeks, during sexual intercourse, how often were you able to maintain your erection after you had penetrated (Table 3 ). These differences were statistically signi®cant (t 4.50, P`0.0001 and t 3.11, P`0.01 respectively). No statistically signi®cant differences were noted among the subgroups of RRP patients with respect to Q 3 4 scores or patient satisfaction, although RRP patients with mixed vascular insuf®-ciency (mean PSV 29 cmasec and mean RI 0.72) tended to have the highest post-treatment IIEF scores (5.4) and sildena®l reponse rate (36%).
Discussion
The sexual rehabilitation of RRP patients is complicated by both the potential for complete or partial lower motor neuron lesion (unilateral vs bilateral nerve loss) and intrinsic versus surgically induced vascular erectile dysfunction. Since its development, the nerve sparing radical retropubic prostatectomy has signi®cantly decreased the rates of ED following radical prostatectomy. 5 While the penile in¯ow from the internal pudendal system should not be disrupted during RRP, the impact of accessory internal pudendal in¯ow remains controversial. 6, 7 Sildena®l is a type V phosphodiesterase inhibitor. Its mechanism of action depends upon intact cavernous nerves to generate nitric oxide (NO) and cause the intracellular accumulation of cyclic GMP. In theory, bilateral ligation of the cavernous nerves would preclude the activity of sildena®l; unilateral nerve ligation or any nerve trauma should downregulate the availabilityaquantity of NO release and thus limit the ef®cacy of sildena®l.
In the current study, RRP patients were classi®ed according to their vascular response to PGE1. All patients claimed preoperative potency, but the nerve sparing status of their operation was unknown. Patients with normal vascular responses to pharmacotesting are highly likely to have neurogenic ED. Indeed, these patients have a signi®cantly higher risk of prolonged erection and true priapism after PGE1 injection. However, patients with abnormal vascular responses to PGE1 challenge may have either vascular dysfunction alone or coexistent neurogenic dysfunction. Based upon the mechanism of action of sildena®l, we expected that patients with normal vascular responses to PGE1 (presumed neurogenic ED) would have the lowest success rates with sildena®l. To the contrary, we found that, while post-RRP patients had lower success rates with sildena®l therapy than did age matched NSED patients, there were no differences among the different subgroups of RRP patients as de®ned by PBFS.
There are several possible explanations for these ®ndings. First and foremost, it is possible that a similar proportion of individuals in both groups had signi®cant injury to the neurovascular bundles bilaterally, which would confound the clinical ef®cacy of sildena®l no matter what the underlying penile vascular status. Since a signi®cant proportion of this group of patients was referred to our institution, we did not have access to operative reports for all patients. Although all surgeries were performed within the last 3 y, it would be erroneous to assume that nerve sparing technique was employed in all cases. In addition, since it is also possible that signi®cant hemodynamic insult may occur as the result of RRP, the very poor response rates among men with RRP and severe arterial insuf®ciency (mean PSV 18 cmasec) is notable.
Our non-surgical group was signi®cantly smaller than our RRP group. This group had similar multiple risk factors for organic ED, and similar postsildena®l Q 3 4 scores to other groups in the literature. 2, 3 We believe they are representative of the`average sildena®l patient' control group.
There are two conceivable ways to sort out the physiologic effects of RRP on patients' erectile performance. The ®rst would be to measure penile blood¯ows before and after surgery; the second would be to demonstrate by some objective measure the degree of neurogenic smooth muscle functionadysfunction as is currently being investigated by corpus cavernosum electromyographs (CCEMGs). Ef®cacy of sildena®l after radical prostatectomy DS Blander et al
The ef®cacy of sildena®l is signi®cantly reduced when the etiology of ED is RRP. Clearly the post-RRP patient can have a variety of medical risk factors for ED (age, HTN, DM, atherosclerotic vascular disease, smoking) in addition to a partial or complete denervation injury. The impact of nerve injury on cavernous smooth muscle physiology has not been characterized. By convention, patients have been advised not to expect full sexual potency until 12 months after operation. The role of a vasoactive stimulant during this recovery phase should be investigated. It may be that in all cases of RRP trauma to the autonomic cavernous nerves may result in transient but decreased nitric oxide signaling to cavernous smooth muscle which might be effectively augmented by a PDE V inhibitor. 8 
Conclusions
Sildena®l is signi®cantly less effective in impotent RRP patients than in age-matched non-surgical patients with ED. We found that sildena®l was equally effective in RRP patients with normal and abnormal responses to PGE1. While individuals with normal vascular responses to PGE1 have an increased likelihood of having neurogenic impotence, among RRP patients, we were unable to demonstrate any difference in ef®cacy of sildena®l.
